Cargando…

The spectrum of opportunistic infections and malignancies among women on antiretroviral therapy in Ethiopia

Background: Women are disproportionally affected by HIV and are at greater risk of OIs and malignancies. This study investigated the spectrum of OIs and malignancies among women living with HIV (WLHIV) in Ethiopia. Methods: A retrospective longitudinal study was conducted among 3,817 WLHIV on Antire...

Descripción completa

Detalles Bibliográficos
Autores principales: Getaneh, Yimam, Getnet, Fentabil, Rashid, Abdur, Kang, Li, Chu, Qingfei, Li, Sisi, Yi, Feng, Shao, Yiming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10614708/
https://www.ncbi.nlm.nih.gov/pubmed/37824698
http://dx.doi.org/10.1080/22221751.2023.2271065
_version_ 1785129078668394496
author Getaneh, Yimam
Getnet, Fentabil
Rashid, Abdur
Kang, Li
Chu, Qingfei
Li, Sisi
Yi, Feng
Shao, Yiming
author_facet Getaneh, Yimam
Getnet, Fentabil
Rashid, Abdur
Kang, Li
Chu, Qingfei
Li, Sisi
Yi, Feng
Shao, Yiming
author_sort Getaneh, Yimam
collection PubMed
description Background: Women are disproportionally affected by HIV and are at greater risk of OIs and malignancies. This study investigated the spectrum of OIs and malignancies among women living with HIV (WLHIV) in Ethiopia. Methods: A retrospective longitudinal study was conducted among 3,817 WLHIV on Antiretroviral Treatment (ART) from 2007 to 2019 in Ethiopia. Data on OIs, malignancies, and clinical characteristics were retrieved from medical records. Prevalence, incidence, and mortality rates were measured over 13 years of follow-up. The Kaplan-Meier survival curve and multivariable Cox-proportional hazard regression were used to estimate incidence and identify predictors of OIs and malignancies, respectively. Result: The pooled prevalence of OIs or malignancies was 47%. OIs accounted for 39% and malignancies were 23.3%. The incidence of OIs and malignancies were 19.4 (95%CI:9.2-29.5) and 11.5 (95%CI:2.2-20.8) per 100 person-years of observation, respectively. Incidence of candidiasis was 14.1 per 100 person-years followed by Lymphoma (11.9), Cervical Cancer (11.5), and TB (10.9). The risk of OIs was higher in patients with baseline CD4 count ≤500 cells/mm3 [AHR (95%CI): 2.0 (1.8-2.3)] and VL>1000 copies/ml [AHR (95%CI): 1.5 (1.1-1.9)]. Overall, 24.6% died, and of them, 62.2% had a history of OIs or malignancies. The risk of death was higher among WLHIV with a history of Toxoplasmosis, TB and PCP. Conclusion: OIs and malignancies was recently increasing and two-thirds of all deaths were associated with these co-morbidities. The high rates of OIs and malignancies were attributed to poor treatment outcomes. The finding calls to enhance the diagnosis and treatment of these co-morbidities. ABBREVIATIONS: AIDS: acquired immune deficiency syndrome; CI: confidence interval; EPHI: Ethiopian Public Health Institute; HAART: highly active antiretroviral therapy; HIV: human immunodeficiency virus; HR: hazard ratio; Mg/dl: milligram per deciliter; TB: tuberculosis; PCP: pneumocystis carinii pneumonia; ZJU: Zhejiang University
format Online
Article
Text
id pubmed-10614708
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-106147082023-10-31 The spectrum of opportunistic infections and malignancies among women on antiretroviral therapy in Ethiopia Getaneh, Yimam Getnet, Fentabil Rashid, Abdur Kang, Li Chu, Qingfei Li, Sisi Yi, Feng Shao, Yiming Emerg Microbes Infect Research Article Background: Women are disproportionally affected by HIV and are at greater risk of OIs and malignancies. This study investigated the spectrum of OIs and malignancies among women living with HIV (WLHIV) in Ethiopia. Methods: A retrospective longitudinal study was conducted among 3,817 WLHIV on Antiretroviral Treatment (ART) from 2007 to 2019 in Ethiopia. Data on OIs, malignancies, and clinical characteristics were retrieved from medical records. Prevalence, incidence, and mortality rates were measured over 13 years of follow-up. The Kaplan-Meier survival curve and multivariable Cox-proportional hazard regression were used to estimate incidence and identify predictors of OIs and malignancies, respectively. Result: The pooled prevalence of OIs or malignancies was 47%. OIs accounted for 39% and malignancies were 23.3%. The incidence of OIs and malignancies were 19.4 (95%CI:9.2-29.5) and 11.5 (95%CI:2.2-20.8) per 100 person-years of observation, respectively. Incidence of candidiasis was 14.1 per 100 person-years followed by Lymphoma (11.9), Cervical Cancer (11.5), and TB (10.9). The risk of OIs was higher in patients with baseline CD4 count ≤500 cells/mm3 [AHR (95%CI): 2.0 (1.8-2.3)] and VL>1000 copies/ml [AHR (95%CI): 1.5 (1.1-1.9)]. Overall, 24.6% died, and of them, 62.2% had a history of OIs or malignancies. The risk of death was higher among WLHIV with a history of Toxoplasmosis, TB and PCP. Conclusion: OIs and malignancies was recently increasing and two-thirds of all deaths were associated with these co-morbidities. The high rates of OIs and malignancies were attributed to poor treatment outcomes. The finding calls to enhance the diagnosis and treatment of these co-morbidities. ABBREVIATIONS: AIDS: acquired immune deficiency syndrome; CI: confidence interval; EPHI: Ethiopian Public Health Institute; HAART: highly active antiretroviral therapy; HIV: human immunodeficiency virus; HR: hazard ratio; Mg/dl: milligram per deciliter; TB: tuberculosis; PCP: pneumocystis carinii pneumonia; ZJU: Zhejiang University Taylor & Francis 2023-10-12 /pmc/articles/PMC10614708/ /pubmed/37824698 http://dx.doi.org/10.1080/22221751.2023.2271065 Text en © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group, on behalf of Shanghai Shangyixun Cultural Communication Co., Ltd https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
spellingShingle Research Article
Getaneh, Yimam
Getnet, Fentabil
Rashid, Abdur
Kang, Li
Chu, Qingfei
Li, Sisi
Yi, Feng
Shao, Yiming
The spectrum of opportunistic infections and malignancies among women on antiretroviral therapy in Ethiopia
title The spectrum of opportunistic infections and malignancies among women on antiretroviral therapy in Ethiopia
title_full The spectrum of opportunistic infections and malignancies among women on antiretroviral therapy in Ethiopia
title_fullStr The spectrum of opportunistic infections and malignancies among women on antiretroviral therapy in Ethiopia
title_full_unstemmed The spectrum of opportunistic infections and malignancies among women on antiretroviral therapy in Ethiopia
title_short The spectrum of opportunistic infections and malignancies among women on antiretroviral therapy in Ethiopia
title_sort spectrum of opportunistic infections and malignancies among women on antiretroviral therapy in ethiopia
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10614708/
https://www.ncbi.nlm.nih.gov/pubmed/37824698
http://dx.doi.org/10.1080/22221751.2023.2271065
work_keys_str_mv AT getanehyimam thespectrumofopportunisticinfectionsandmalignanciesamongwomenonantiretroviraltherapyinethiopia
AT getnetfentabil thespectrumofopportunisticinfectionsandmalignanciesamongwomenonantiretroviraltherapyinethiopia
AT rashidabdur thespectrumofopportunisticinfectionsandmalignanciesamongwomenonantiretroviraltherapyinethiopia
AT kangli thespectrumofopportunisticinfectionsandmalignanciesamongwomenonantiretroviraltherapyinethiopia
AT chuqingfei thespectrumofopportunisticinfectionsandmalignanciesamongwomenonantiretroviraltherapyinethiopia
AT lisisi thespectrumofopportunisticinfectionsandmalignanciesamongwomenonantiretroviraltherapyinethiopia
AT yifeng thespectrumofopportunisticinfectionsandmalignanciesamongwomenonantiretroviraltherapyinethiopia
AT shaoyiming thespectrumofopportunisticinfectionsandmalignanciesamongwomenonantiretroviraltherapyinethiopia
AT getanehyimam spectrumofopportunisticinfectionsandmalignanciesamongwomenonantiretroviraltherapyinethiopia
AT getnetfentabil spectrumofopportunisticinfectionsandmalignanciesamongwomenonantiretroviraltherapyinethiopia
AT rashidabdur spectrumofopportunisticinfectionsandmalignanciesamongwomenonantiretroviraltherapyinethiopia
AT kangli spectrumofopportunisticinfectionsandmalignanciesamongwomenonantiretroviraltherapyinethiopia
AT chuqingfei spectrumofopportunisticinfectionsandmalignanciesamongwomenonantiretroviraltherapyinethiopia
AT lisisi spectrumofopportunisticinfectionsandmalignanciesamongwomenonantiretroviraltherapyinethiopia
AT yifeng spectrumofopportunisticinfectionsandmalignanciesamongwomenonantiretroviraltherapyinethiopia
AT shaoyiming spectrumofopportunisticinfectionsandmalignanciesamongwomenonantiretroviraltherapyinethiopia